대한신장학회

Skip Navigation: Skip to contents

KOR
ENG
전체메뉴보기

간행물 검색

현재 페이지 경로

HOME
간행물
간행물 검색

논문분류	춘계학술대회 초록집
제목	Impact of Finerenone on Circulating Mitokines in Diabetic Kidney Disease
저자	Haekyung Lee
출판정보	2026; 2026(1):
키워드	Diabetic kidney disease, Finerenone, Mitokine
초록	Objectives: Mitokines are released in response to cellular stress and play important roles in metabolic and physiological processes. Finerenone, a non-steroidal mineralocorticoid receptor antagonist, is a cornerstone therapy for diabetic kidney disease (DKD). This study aimed to investigate the effects of finerenone on circulating mitokine levels in individuals with DKD. Methods: Individuals with finerenone-naïve DKD (n = 42; 88.1% receiving sodium–glucose cotransporter 2 inhibitors) and healthy controls (n = 35) were prospectively enrolled. Circulating levels of fibroblast growth factor 21 (FGF21), growth differentiation factor 15 (GDF15), humanin, and mitochondrial open reading frame of the 12S rRNA-c (MOTS-c) were measured using ELISA. In individuals with DKD, mitokine levels were reassessed at 3 and 6 months after initiation of finerenone treatment. Results: Individuals with DKD were older and had a higher body mass index and albuminuria, and a lower estimated glomerular filtration rate (all P < 0.001). Compared with healthy controls, GDF15 levels were lower, whereas FGF21 and humanin levels were higher, in the finerenone group (all P < 0.001; Fig. 1). MOTS-c levels did not differ between the groups (P = 0.250; Fig. 1). After finerenone treatment, humanin levels decreased at 3 months but increased again at 6 months (all P < 0.001). In addition, at 6 months, GDF15 and MOTS-c levels increased, while FGF21 levels decreased (all P < 0.001). At 6 months of finerenone treatment, 71.43% of patients achieved a ≥30% reduction in albuminuria, and there were no differences in circulating mitokine levels between patients with and without a ≥30% reduction in albuminuria. Conclusion: DKD is associated with dysregulated circulating mitokine levels. Finerenone treatment resulted in dynamic changes in mitokine levels, which appeared after 3 months of treatment. These findings suggest that finerenone therapy may mitigate mitochondrial dysfunction in individuals with DKD.
원문(PDF)	PDF 원문보기

목록

위로가기